CN109988185B - 具有抗肿瘤选择性的铂镝杂金属化合物及其制备方法 - Google Patents
具有抗肿瘤选择性的铂镝杂金属化合物及其制备方法 Download PDFInfo
- Publication number
- CN109988185B CN109988185B CN201910386015.9A CN201910386015A CN109988185B CN 109988185 B CN109988185 B CN 109988185B CN 201910386015 A CN201910386015 A CN 201910386015A CN 109988185 B CN109988185 B CN 109988185B
- Authority
- CN
- China
- Prior art keywords
- dysprosium
- platinum
- metal compound
- tro
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 23
- YYEDUMQWQGBXQK-UHFFFAOYSA-N dysprosium platinum Chemical compound [Dy].[Pt] YYEDUMQWQGBXQK-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 150000002736 metal compounds Chemical class 0.000 title abstract description 11
- 238000002360 preparation method Methods 0.000 title abstract description 8
- MDYOLVRUBBJPFM-UHFFFAOYSA-N tropolone Chemical compound OC1=CC=CC=CC1=O MDYOLVRUBBJPFM-UHFFFAOYSA-N 0.000 claims abstract description 24
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 7
- 239000011521 glass Substances 0.000 claims abstract description 6
- 229910000069 nitrogen hydride Inorganic materials 0.000 claims abstract description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 claims abstract description 5
- NOTQUFQJAWMLCE-UHFFFAOYSA-N dysprosium(3+) trinitrate pentahydrate Chemical compound O.O.O.O.O.[Dy+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O NOTQUFQJAWMLCE-UHFFFAOYSA-N 0.000 claims abstract description 5
- CLSUSRZJUQMOHH-UHFFFAOYSA-L platinum dichloride Chemical compound Cl[Pt]Cl CLSUSRZJUQMOHH-UHFFFAOYSA-L 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims abstract description 5
- 238000001816 cooling Methods 0.000 claims abstract description 4
- 238000007789 sealing Methods 0.000 claims abstract description 3
- 238000005303 weighing Methods 0.000 claims abstract description 3
- 239000013078 crystal Substances 0.000 claims description 10
- 239000003446 ligand Substances 0.000 claims description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 7
- 150000001768 cations Chemical class 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 150000002500 ions Chemical class 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 3
- -1 platinum dysprosium hetero metal compound Chemical class 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 150000001450 anions Chemical class 0.000 claims description 2
- 239000013522 chelant Substances 0.000 claims description 2
- RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical group [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 10
- 210000004881 tumor cell Anatomy 0.000 abstract description 10
- 238000011160 research Methods 0.000 abstract description 5
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 abstract description 2
- 210000005229 liver cell Anatomy 0.000 abstract description 2
- 239000002246 antineoplastic agent Substances 0.000 description 9
- 229940041181 antineoplastic drug Drugs 0.000 description 9
- 150000004696 coordination complex Chemical class 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 231100000053 low toxicity Toxicity 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 229910052692 Dysprosium Inorganic materials 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000012327 Ruthenium complex Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000004699 copper complex Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
具有较强抗肿瘤选择性的铂镝杂金属化合物及其制备方法，其化学式为：[NH4]2[Pt(NH3)3(H2O)][Dy(Tro)4]4·3H2O.(Tro为脱一个氢离子的环庚三烯酚酮)。其制备方法是：称取二氯化铂和五水硝酸镝及环庚三烯酚酮于封底硬质玻璃管中，加入氨水及DMF溶剂，封口，在60‑85℃下反应2‑3天，降温，即得标题化合物。研究结果表明该铂镝杂金属化合物的抗肿瘤活性对肿瘤细胞具有较好的选择性，铂镝杂金属化合物对正常肝细胞HL‑7702的IC50值>100μmol·mL‑1，说明它对人体正常细胞的毒性低。
Description
技术领域
本发明涉及抗肿瘤药物，具体涉及一种具有抗肿瘤选择性的铂镝杂金属化合物，还涉及金属化合物的制备方法。
背景技术
抗肿瘤药物种类繁多，发展迅速，科研人员一直坚持不懈进行抗肿瘤药物的研究，取得了一定的成就。但许多药物针对性不强，副作用大，抗肿瘤活性并不理想。因此，探索选择性强，只对肿瘤细胞有效，而对正常细胞毒性低的新型抗肿瘤药物是科研人员的努力方向和研究目标。
目前，金属配合物在医药领域已得到广泛应用，如早期肿瘤检测试纸。在抗肿瘤新药研究领域，金属配合物对肿瘤的治疗产生了巨大影响，如顺铂已成为临床上一种重要的抗肿瘤药物，对肺癌、骨癌以及早期卵巢癌等有明显的抗肿瘤效果。金属配合物是利用金属离子与配体的协同作用来达到抗肿瘤效果，研究证明配合物的生物活性优于配体原本的活性，比原本配体的有效成分具有更显著的抗肿瘤活性，减轻配体药物毒性。
以金属配合物为研究对象的抗肿瘤药物，在设计路线和合成方法上取得了突破性进展，主要包括铂类金属配合物，铜配合物，钌配合物等。最近也有报道某些稀土金属配合物具有一定的抗肿瘤作用，但将铂配合物与镝配合物组合成一个化合物用于抗肿瘤选择性分析尚未见报道。
发明内容
本发明要解决的技术问题是提供一种新型的抗肿瘤药物，即一种具有抗肿瘤选择性的铂镝杂金属化合物，同时提供该金属配合物的制备方法，对MGC803与T-24等肿瘤细胞具有较强的抗肿瘤活性，而对Hep-G2和H460等肿瘤细胞活性较差，对正常细胞毒性低。
实现本发明目的的技术方案是：
具有抗肿瘤选择性的铂镝杂金属化合物，其化学式为：[NH4]2[Pt(NH3)3(H2O)][Dy(Tro)4]4·3H2O(Tro为脱一个氢离子的环庚三烯酚酮)
该化合物的化学式表示它有两个[NH4]+阳离子、一个[Pt(NH3)3(H2O)]2+阳离子、四个[Dy(Tro)4]-阴离子及三结晶水分子组成。图1为该配合物的不对称单元，即该化合物的化学式所示组成的一半。[Pt(NH3)3(H2O)]2+阳离子中的Pt(II)离子被三个NH3分子与一个H2O分子配位形成平面四方结构。[Dy(Tro)4]-阴离子中的Dy(III)离子均被四个脱氢的托酚酮配体(Tro-)以双齿螯合形式配位形成一个八配位的十二面体构型。
该化合物属于单斜晶系，C2/c空间群，晶胞参数为：
α＝90.00°，β＝110.752(3)°，γ＝90.00°，
本发明铂镝杂金属化合物的制备方法，其操作步骤是：
称取二氯化铂和五水硝酸镝及环庚三烯酚酮于10*200mm的一个封底硬质玻璃管中，然后在其缓慢加入25～28％的氨水溶液及溶剂，摇匀后封口；在加热60～85℃条件下反应2-3天，取出后缓慢降温至室温，用溶剂进行洗涤，得到淡黄色片状晶体。
所述溶剂为DMF和水混合溶剂,在不断的改变DMF和水之间的比例后，得到DMF和水为3:1时最好。
所述加热条件下反应是75～85℃的条件下进行。
与现有技术相比，本发明提供了一种新型的抗肿瘤化合物以及它的制备方法。该化合物对某些特定的肿瘤细胞具有较强的抗肿瘤活性，对人体正常细胞毒性低。对MGC803与T-24等肿瘤细胞具有较强的抗肿瘤活性，而对Hep-G2和H460等肿瘤细胞活性较差，对正常细胞毒性低。在抗肿瘤药物领域具有潜在的应用价值。
附图说明
图1是本发明实施例1所得产物的分子结构图。
具体实施方式
下面结合具体实施例对本发明作进一步的详述,以更好地理解本发明的内容,但本发明并不限于以下实施例。
实施例1：称取二氯化铂(0.05mmol，13.3mg)和五水硝酸镝(0.05mmol，21.6mg)及环庚三烯酚酮(0.015mmol，18.3mg)置于10*200mm的自制的封底硬质玻璃管中，然后再缓慢加入25-28％的氨水溶液50μL、DMF(1.5mL)和H2O(0.5mL)，摇匀后封口。放于80℃的烘箱中反应三天。取出后缓慢降至室温。用溶剂进行洗涤，得到淡黄色片状晶体。真空干燥得0.0332g，产率为40％。
对实施例1所得产物进行表征及性能测定：
1)结构表征：
挑选合适的配合物的单晶，置于SuperNova X-射线单晶衍射仪上，采用石墨单色化Mo-Kα辐射
在296K条件下，在一定的θ范围内以φ-ω扫描方式收集衍射点用于结构解析和修正。非氢原子用直接法解出，并对其坐标及各向异性热参数进行用全矩阵最小二乘法修正。混合加氢，氢原子采用各向同性热参数；非氢原子采用各向异性热参数。晶体结构的解析和结构修正分别由SHELX-97和SHELXL程序包完成。详细的晶体测定数据见表1，其分子结构如图1所示。
表1实施例1所得产物的结构表征数据
2)抗肿瘤活性测定
我们对铂镝杂金属化合物做了MGC803、T-24、Hep-G2、H460和HL-7702几种细胞的抑制率和半数杀伤浓度测定实验，采用MTT法(吸光度表示细胞在溶液中的密度，基于朗伯-比尔定律)进行测定。以DMSO为溶剂，将环庚三烯酚酮与铂镝杂金属化合物配成0.2mmol/mL的储备液。结果见表2。
表2抗肿瘤活性测定
铂镝杂金属化合物对MGC803与T-24肿瘤细胞株的IC50值均比环庚三烯酚酮配体要小得多，体现了该铂镝杂金属化合物对这些肿瘤细胞的抗肿瘤活性比环庚三烯酚酮配体要强得多。铂镝杂金属化合物与环庚三烯酚酮配体对Hep-G2和H460肿瘤细胞的IC50值都较高，说明它们对这些癌细胞的活性较差。这些说明铂镝杂金属化合物对肿瘤细胞具有较好的选择性。
铂镝杂金属化合物对正常肝细胞HL-7702的IC50值>100μmol·mL-1，说明它对人体正常细胞的毒性低。
Claims (4)
1.具有抗肿瘤选择性的铂镝杂金属化合物，其化学式为：[NH4]2[Pt(NH3)3(H2O)][Dy(Tro)4]4·3H2O；
该化合物有两个[NH4]+阳离子、一个[Pt(NH3)3(H2O)]+阳离子、四个[Dy(Tro)4]-阴离子及三结晶水分子组成；
[Pt(NH3)3(H2O)]+阳离子中的Pt(II)离子被三个NH3分子与一个H2O分子配位形成平面四方结构；
[Dy(Tro)4]-阴离子中的Dy(III)离子均被四个脱氢的托酚酮配体(Tro-)以双齿螯合形式配位形成一个八配位的十二面体构型。
2.根据权利要求1 所述具有抗肿瘤选择性的铂镝杂金属化合物，其特征是：
该化合物属于单斜晶系，C2/c空间群，晶胞参数为：
α＝90.00°，β＝110.752(3)°，γ＝90.00°，
3.根据权利要求1所述的具有抗肿瘤选择性的铂镝杂金属化合物的制备方法，其特征是：称取二氯化铂和五水硝酸镝及环庚三烯酚酮于自制的封底硬质玻璃管中，然后缓慢加入25-28％的氨水溶液及DMF和水，摇匀后封口；在60～85℃条件下加热反应2-3天，取出后缓慢降温至室温，用溶剂进行洗涤，得到淡黄色片状晶体。
4.根据权利要求3所述的制备方法，其特征是：各原料用量是0.05mmol二氯化铂﹕0.05mmol五水硝酸镝﹕0.015mmol环庚三烯酚酮＝133﹕216﹕183mg，氨水溶液50μL、DMF1.5mL和水0.5mL。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910386015.9A CN109988185B (zh) | 2019-05-09 | 2019-05-09 | 具有抗肿瘤选择性的铂镝杂金属化合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910386015.9A CN109988185B (zh) | 2019-05-09 | 2019-05-09 | 具有抗肿瘤选择性的铂镝杂金属化合物及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109988185A CN109988185A (zh) | 2019-07-09 |
| CN109988185B true CN109988185B (zh) | 2021-03-19 |
Family
ID=67136306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910386015.9A Active CN109988185B (zh) | 2019-05-09 | 2019-05-09 | 具有抗肿瘤选择性的铂镝杂金属化合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109988185B (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1145624A (zh) * | 1994-03-31 | 1997-03-19 | 意大利柏林格·曼海姆股份公司 | 具有抗肿瘤活性的三核阳离子铂络合物及含有它们的药用组合物 |
| CN1569862A (zh) * | 2003-06-11 | 2005-01-26 | 南京大学 | 抗肿瘤铂（ⅱ）配合物 |
-
2019
- 2019-05-09 CN CN201910386015.9A patent/CN109988185B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1145624A (zh) * | 1994-03-31 | 1997-03-19 | 意大利柏林格·曼海姆股份公司 | 具有抗肿瘤活性的三核阳离子铂络合物及含有它们的药用组合物 |
| CN1569862A (zh) * | 2003-06-11 | 2005-01-26 | 南京大学 | 抗肿瘤铂（ⅱ）配合物 |
Non-Patent Citations (2)
| Title |
|---|
| "CRYSTAL FIELD ASPECTS OF VIBRATIONAL SPECTRA";L.G.HULETT et al.,;《Journal of Molecular Structure 》;19720731;第13卷(第1期);第115-127页 * |
| "Synthesis and Structural Properties of Lanthanide Complexes Formed with Tropolonate Ligands";Jian Zhang et al.,;《Inorganic Chemistry》;20070710;第46卷(第16期);第6473-6482页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109988185A (zh) | 2019-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bhattacharya et al. | Bis (nitrate) diaquauranyl (vi) synthon to generate [1× 2+ 1× 1] and [1× 1+ 1× 1] co-crystalized 3d⋯ 5f self-assemblies | |
| Maclaren et al. | Amino-acid based coordination polymers | |
| Van Kralingen et al. | Synthesis and characterization of antitumor-active platinum 2, 2-dimethyl-1, 3-diaminopropane compounds. Crystal and molecular structure of (malonato)(2, 2-dimethyl-1, 3-diaminopropane) platinum (II) | |
| Graves et al. | Synthesis and structural characterization of cis-dichlorobis (N-methylimidazole) platinum (II) and cis-dibromobis (N-methylimidazole) platinum (II) | |
| Ji et al. | Copper (I) halide clusters based upon ferrocenylchalcogenoether ligands: donors, halides and semi-rigidity effects on the geometry and catalytic activity | |
| Al-Jibori et al. | Platinum and palladium bis (diphenylphosphino) ferrocene (dppf) complexes with heterocyclic N-acetamide ligands: Synthesis and molecular structures of [MCl (sac)(κ2-dppf)](M= Pt, Pd, sac= saccharinate),[PtCl (ata)(κ2-dppf)] and [Pt (ata) 2 (κ2-dppf)](ataH= N-(2-thiazolyl) acetamide) | |
| Al-Jaroudi et al. | Synthesis, spectroscopic characterization, X-ray structure and electrochemistry of new bis (1, 2-diaminocyclohexane) gold (III) chloride compounds and their anticancer activities against PC3 and SGC7901 cancer cell lines | |
| Kuhn et al. | {Ph2 (Carb) P} MCl3 (M= Pd, Pt; Carb= 2, 3‐dihydro‐1, 3‐diisopropyl‐4, 5dimethylimidazol‐2‐ylidene)–a Novel Cationic Phosphane Ligand [1] | |
| Chandrasekhar et al. | Ferrocene-based compartmental ligand for the assembly of neutral Zn II/Ln III heterometallic complexes | |
| Rotondo et al. | Synthesis and NMR investigation of dirhodium (4+) formamidinate complexes containing 2-(diphenylphosphino) pyridine as a bridging ligand. X-ray crystal structure of the complex Rh2 (form) 2 (. mu.-PPh2Py) 2 (O2CCF3) 2 (form= N, N'-di-p-tolylformamidinate) | |
| CN109988185B (zh) | 具有抗肿瘤选择性的铂镝杂金属化合物及其制备方法 | |
| Huang et al. | Gold (I) vs gold (III): stabilization of two gold (I) polyselenide complexes,[Au2 (Se2)(Se3)] 2-and [Au2 (Se2)(Se4)] 2-, by the diselenide unit | |
| Imhoff et al. | Iminophosphorane complexes of rhodium (I) and X-ray crystal structure of [Rh (COD) Cl (Et3P Np-tolyl)] | |
| Xu et al. | Antitumor platinum (II) complexes of N-cyclobutyl-1R, 2R-diaminocyclohexane with dicarboxylates as leaving groups | |
| Lee et al. | Cationic diamineplatinum (II) complexes of nalidixic acid | |
| Quintal et al. | Synthesis and properties of new trinuclear Mo (II) complexes containing imidazole and benzimidazole ferrocene units | |
| Ciabatti et al. | Co5C and Co4C carbido carbonyl clusters stabilized by [AuPPh3]+ fragments | |
| Zhou et al. | Enantiomeric and mesomeric mandelate complexes of molybdenum–on their stereospecific formations and absolute configurations | |
| Karaağaç et al. | Syntheses, crystal structures, spectroscopic and thermal analyses of 3-and 4-aminomethylpyridinium tetracyanometallate (II) complexes | |
| CN112279814B (zh) | 一种铜(ii)配合物及其制备方法与应用 | |
| Zhang et al. | Anion-tuned self-assembly of zinc (II)–fluconazole complexes: Crystal structures, luminescent and thermal properties | |
| CN111116616B (zh) | 一种锌的Schiff碱配合物的制备方法及其应用 | |
| Bandoli et al. | Synthesis and structure of the first neutral octahedral cis-dioxorhenium (V) complex | |
| Xia et al. | A 3D In (III) coordination polymer derived from rigid dicarboxylate ligand: Synthesis, crystal structure and catalytic property | |
| Guo et al. | Well-defined lanthanum ethylenediaminetetraacetates as the precursors of catalysts for the oxidative coupling of methane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |